Institute of the Cervix, Federation Mutualiste Parisienne, 174 Rue de Courcelles, 75017 Paris, France.
Vaccine. 2010 Nov 29;28(51):8065-72. doi: 10.1016/j.vaccine.2010.10.017. Epub 2010 Nov 16.
Cervical cancer is a leading cause of cancer-related deaths worldwide. The causal role of human papillomavirus (HPV) infection in the pathogenesis of cervical cancer has prompted the development of vaccines against HPV. The highest risk of HPV infection is in women aged 16-25 years. Almost all young adult women can benefit from HPV vaccination. There is strong epidemiological and clinical support for vaccination programmes that target sexually active women in this age group to prevent HPV infection, and thus avert the development of HPV-related disease. Furthermore, the implementation of HPV vaccination programmes may benefit the development or awareness of cervical cancer prevention strategies and ultimately reduce the burden of cervical cancer and improve cervical cancer control.
宫颈癌是全球癌症相关死亡的主要原因。人乳头瘤病毒（HPV）感染在宫颈癌发病机制中的因果作用促使开发了 HPV 疫苗。HPV 感染的最高风险发生在 16-25 岁的女性中。几乎所有年轻成年女性都可以从 HPV 疫苗接种中受益。针对该年龄组有性行为的女性的疫苗接种计划具有强有力的流行病学和临床支持，以预防 HPV 感染，从而避免 HPV 相关疾病的发生。此外，实施 HPV 疫苗接种计划可能有助于制定或提高宫颈癌预防策略的认识，并最终减轻宫颈癌负担，改善宫颈癌控制。
